ArticleJournal of gastrointestinal oncology2025
Liver microsomal protein content and activity in patients with hepatocellular carcinoma and cirrhosis: implications for the
Article in Journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Toward adaptive therapeutic timing: integration of mechanistic pharmacology and artificial intelligence in precision dosing.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The hepatic metabolism of patients with hepatocellular carcinoma and cirrhosis (HCCC) may differ from that of patients with hepatocellular carcinoma (HCC) without cirrhosis, limiting the clinical individualized dosing regimens for these patients. Microsomal protein per gram of liver (MPPGL) is an important scaling factor for physiologically based pharmacokinetic models, but data in patients with HCCC are limited. The study aims to determine the content of MPPGL in patients with HCCC and to guide individualized clinical dosing of patients with HCCC using Methods: The microsomal protein content was determined in liver samples of patients with HCCC (n=48) and in normal liver samples (n=68). The activity of 10 cytochrome P450 (CYP) isoforms at the microsomal protein level (CL Results: The median value of MPPGL was significantly lower in patients with HCCC (28.35 mg/g) than in the controls (37.65 mg/g) (P=0.008). In patients with HCCC as compared to controls, the CL Conclusions: In patients with HCCC, MPPGL content was significantly reduced, and a variable change in the activity of 10 CYP was observed in microsomes. When taking individual MPPGL into account, CL
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.